🔍 Pharmidex In Silico Drug Discovery – Step 3: Determination of Active/Binding Sites! 🎯💻

February 25, 2025

At Pharmidex, we continue to push the boundaries of computational drug discovery! Following target structure and ligand determination, our advanced Determination of Active/Binding Sites step ensures precise identification of key molecular interactions, optimizing drug design for success.

✨ Why is this step crucial?

✅ Accurate identification of binding pockets for targeted drug interactions

✅ AI-powered pocket detection and molecular dynamics simulations

✅ Enhanced precision in hit identification and lead optimization

✅ Seamless integration with our next in silico pipeline steps

By leveraging cutting-edge computational tools, we de-risk drug development and accelerate therapeutic innovation. Stay tuned for the next stage in our in silico pipeline!

📽️ Watch our latest video (2/5) to explore how we map active sites with precision!

📩 Let’s collaborate to revolutionize drug discovery!

#DrugDiscovery #Pharmidex #AIinBiotech #MolecularModeling #PharmaceuticalInnovation

< Older Post

Newer Post >

Thanks to our interns from City St George’s, University of London

June 19, 2026

A big thank you to our interns from City St George’s, University of London and heir fantastic contribution to Pharmidex over the past few months. They have supported scientific projects across the business, developed valuable technical skills and gained hands-on experience within a CRO environment. Their contribution has extended beyond the laboratory, helping with our website, marketing materials, conference preparation and business development activities. Science drives success, but communicating that science effectively is just as important. Our interns have helped us do both. Thank you for your hard work, enthusiasm, and dedication. We wish you every success in the next stage of your careers.

Pharmidex at the "Creative Disruption Forum: Modern Drug Discovery in Cambridge."

June 17, 2026

On 18 June, our COO, Ash Alavijeh , will join an industry panel discussing: "What are the advantages and disadvantages of working with UK-based Discovery CROs?" The session will explore the value of UK CROs in supporting innovation, protecting IP, accessing scientific expertise and accelerating drug discovery programmes. 📅 18 June 2025 📍 Cambridge 🕒 Panel Session: 12:20–12:45 We look forward to connecting with colleagues, collaborators, and innovators from across the life sciences community.

Congratulate Dr Mansoor Chishty as Director of DMPK at Pharmidex

June 16, 2026

This well-deserved appointment marks an important milestone in a remarkable career spanning more than 22 years at Pharmidex . Over the years, Dr Chishty has made a significant contribution to the growth of our DMPK capabilities, applying his extensive expertise in Drug Metabolism and Pharmacokinetics to support successful drug discovery and development programmes for clients worldwide. His scientific leadership, dedication and commitment to excellence have been instrumental in strengthening our services and supporting the continued success of Pharmidex . As we continue to grow and support innovative biopharmaceutical companies, we look forward to the impact Dr Chishty will make in this new role. Please join us in congratulating Dr Mansoor Chishty on this achievement and wishing him every success as Director of DMPK.